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A number of developments have altered the treatment paradigm for metastatic non-small
cell, non-squamous lung cancer. These include increasing knowledge of molecular signal
pathways, as well as the outcomes of several large-scale trials. As a result, treatments
are becoming more efficacious and more personalized, and are changing the management
and prognosis of non-small cell lung cancer patients. This is resulting in increased survival
in select patient groups. In this paper, a simplified algorithm for treating patients with
metastatic non-small cell, non-squamous lung cancer is presented.
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TREATMENT PARADIGMS
The previous standard of care in metastatic non-small cell lung
cancer (NSCLC) was to treat patients with a platinum doublet
for four to six cycles and to offer second-line therapy upon pro-
gression (1). The emergence of molecular testing, specifically for
the epidermal growth factor receptor (EGFR) and for anaplas-
tic lymphoma kinase (ALK), enables us to better tailor treatment
strategies. The results from many recent large-scale clinical trials
have validated these new treatment approaches.
Chemotherapy is still one of our most important weapons.
Patients are now surviving longer. All patients should get three
lines of therapy. With more treatment options becoming available,
algorithms must be strategically designed to balance the need to
give the best drugs first while ensuring that there are many more
options available for later.
The treatment algorithm discussed in this chapter is based
on Canadian recommendations. Although other health author-
ities may have different therapeutics available, basic principles still
apply.
FIRST TREATMENT DECISION POINT: HISTOLOGY AND
MUTATION TESTING
HISTOLOGY
In the past, the only histological criterion for therapeutic deci-
sion making was whether the lung cancer was small cell or non-
small cell. The distinction between squamous or non-squamous
cell histology became important and with the evolution of
Abbreviations: ATP, adenosine triphosphate; ALK, anaplastic lymphoma kinase;
EGFR, epidermal growth factor receptor; HER 2, human epidermal growth factor
receptor 2; NCI, National Cancer Institute; NSCLC, non-small cell lung cancer; RCT,
randomized clinical trial; OS, overall survival; PFS, progression free survival; TKI,
tyrosine kinase inhibitor.
immunostaining, this distinction has become more evident. The
reported incidence of squamous cell lung cancer has decreased
over the last several decades (2), which may be due to natural phe-
nomena or to the development of better immunostaining. For this
same reason, the reported incidence of large cell, squamous, and
non-small cell (otherwise unspecified) cancer is decreasing and the
incidence adenocarcinoma is increasing. The emergence of more
molecular tests is unlikely to lessen the importance of histology.
MUTATIONAL TESTING
Mutation status influences the selection of first-line therapies. At
this time, testing for EGFR mutations and for rearrangements in
the ALK gene is recommended for patients with non-squamous
histology. A number of initiatives are underway to help ensure
that all advanced lung cancer patients will have mutation and bio-
marker testing available. Cooperation of all specialties is required,
including respirologists, interventional radiologists, surgeons, and
pathologists (3, 4).
Mutation profiles of cancer continue to rapidly evolve, espe-
cially for adenocarcinomas. As we better understand how other
gene mutations influence lung cancer, mutation testing for other
targets including MET, RET, and KRAS (5, 6) will become more
likely and treatment algorithms will become even more complex.
TREATMENT OPTIONS FOR NON-SQUAMOUS NSCLC
Histological analysis determines if patients have tumors with squa-
mous or non-squamous histology. This chapter discusses non-
squamous histology only. With mutation testing, patients can be
divided into three groups: those whose tumors are positive for
the EGFR mutation, which is 10–30% (6) (group A); those whose
tumors are positive for the ALK mutation, approximately 5–7% (6)
(group B); and those whose tumors do not have mutations in either
EGFR or ALK or their mutation status is unknown, approximately
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63–85% (group C). Therapy is selected based on these distinctions
(Figure 1).
GROUP A: EPIDERMAL GROWTH FACTOR RECEPTOR
MUTATION POSITIVE
FIRST LINE
Activity of EGFR is inhibited by tyrosine kinase inhibitors (TKIs),
a unique class of orally administered, small molecule therapeutics
that have found their way into the standard of care treatment
in almost all types of malignancy. Several trials have demon-
strated that TKIs, including erlotinib (7), gefitinib (8), and afa-
tinib (9, 10), are efficacious first-line treatments for this patient
population.
The efficacy of gefitinib was demonstrated in the IPASS trial,
which compared first-line gefitinib with a carboplatin/paclitaxel
doublet in an EGFR-unselected population. Although the
gefitinib-treated patients demonstrated no increase in overall sur-
vival (OS), the time to progression (9.5 versus 6.3 months, respec-
tively, HR 0.48; 95% CI 0.36 versus 0.64; P < 0.0001), overall
response rate (71.2 versus 47.3%), and quality of life was improved
in a subset of patients with EGFR-mutated tumors (8).
Erlotinib was shown to be advantageous in the first-line setting
in the phase III EURTAC trial, where erlotinib-treated patients
with EGFR mutation-positive tumors experienced progression
free survival (PFS) of 9.7 months as compared to 5.2 months
(HR= 0.37; P< 0.0001) in those patients treated with a platinum-
based doublet such as docetaxel or gemcitabine (11). Response rate
was 58% in the erlotinib arm versus 15% in the chemotherapy arm
(P< 0.0001).
Afatinib has been shown to be superior to chemotherapy in the
first line, in both the LUX-LUNG 3 (12) and the LUX-LUNG 6
(10) trials. LUX-LUNG3 was a phase III trial comparing afatinib
versus chemotherapy (cisplatin/pemetrexed) as first-line treat-
ments in chemo-naïve, NSCLC patients with EGFR mutation-
positive tumors. LUX-LUNG 3 demonstrated that in the overall
study population, median PFS was significantly longer with afa-
tinib as compared to chemotherapy (11.1 versus 6.9 months; HR
0.58, 95% CI 0.43–0.78; P = 0.0004) (12). In patients with com-
mon EGFR mutation-positive tumors, median PFS was 13.6 versus
6.9 months on chemotherapy.
LUX-LUNG 6, a trial comparing afatinib with cis-
platin/gemcitabine, confirmed that afatinib significantly improves
PFS with a tolerable and manageable safety profile in Asian patients
with advanced NSCLC who had tumors with EGFR mutations.
In the overall study population, median PFS was significantly
longer with afatinib as compared to chemotherapy (11.0 versus
5.6 months; HR 0.28, 95% CI 0.20–0.39; P < 0.0001) (10).
Selecting the TKI in this situation depends on many factors
and is discussed in great detail elsewhere (13). Erlotinib and gefi-
tinib are first generation TKIs, while afatinib and dacomitinib
are second generation TKIs. Second generation TKIs differ from
first generation. They block more ligands of the HER family. Per-
haps more importantly, they are non-competitive inhibitors at the
kinase site, so theoretically should prove to be more effective or
confer a longer period to resistance than the first generation TKIs.
We await the results and publication of several pivotal dacomitinib
trials. Patient performance status, comorbidities, and age will all
come into play in the decision making, as well as the availabil-
ity of each therapeutic in a particular health authority. Unlike
chemotherapy, TKIs can often be continued past progression in
the lung cancer context, as long as there is a clinical benefit to the
patient.
FIGURE 1 | A simplified treatment algorithm for patients with metastatic non-small cell non-squamous lung cancer. Patients are divided into three
groups based on histology and EGFR and ALK mutation status. Selection of therapies is based on these groups. The dashed boxes indicate that maintenance is
optional in group C patients.
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SECOND-LINE THERAPY (FIRST-LINE SYSTEMIC THERAPY)
For all mutation-positive patients, the second-line therapy is
the standard chemotherapy: a platinum doublet such as plat-
inum/pemetrexed for four to six cycles (1). A single agent, such as
pemetrexed, is an option for patients who are elderly or who may
have a poor performance status and are not candidates for a plat-
inum doublet. After second-line therapy, the patient is observed
until progression.
THIRD LINE THERAPY
Selection of third line therapy in these patients is straightforward;
the single agent that has not been used so far. In most cases, this
will be either docetaxel or pemetrexed to be continued until dis-
ease progression. After disease progression, patients with adequate
performance status may be considered for clinical trials.
GROUP B: ANAPLASTIC LYMPHOMA KINASE MUTATION
POSITIVE
FIRST-LINE THERAPY
Anaplastic lymphoma kinase gene rearrangements are found more
commonly in adenocarcinomas than other types of lung cancers,
and also found more commonly in light smokers or non-smokers.
ALK gene rearrangements are thought to be exclusive of EGFR
and KRAS mutations and occur in approximately 4–7% of lung
cancers (6).
Patients with chromosomal rearrangements of the ALK gene
have shown to have a stronger clinical response to crizotinib, an
ALK-targeted TKI. A phase I trial in patients with advanced ALK-
positive NSCLC demonstrated that crizotinib is associated with
higher response rates and improved survival compared to that of
crizotinib-naive controls (14), and as a result, received approval
from FDA in the US and Health Canada in 2011 for use in this
patient population.
Crizotinib was shown to be superior to standard chemother-
apy in ALK mutation-positive pre-treated patients with advanced
NSCLC (median PFS 7.7 months in the crizotinib group ver-
sus 3.0 months in the chemotherapy group (HR, 0.49; 95%
CI, 0.37–0.64; P < 0.001); response rates 65% (95% CI, 58–72)
for crizotinib versus 20% (95% CI, 14–26) with chemother-
apy (P < 0.001) (15). Although this trial was conducted in
pre-treated patients, using a drug that specifically inhibits the
ALK pathway is perfect rationale to provide this treatment in
the first-line. NCCN guidelines have recommended a first-line
approach. Newly released results from the PROFILE 1014 phase
III trial showed that crizotinib significantly prolonged PFS as





reflink=MW_news_stmp. Accessed on April 4, 2014).
As with the other TKIs, crizotinib is often continued past
progression as long as there is a clinical benefit to the patient.
SECOND AND THIRD LINE THERAPY
Advanced NSCLC patients positive for the ALK mutation now have
a new second-line agent (16). In April 2014, the FDA approved cer-
itinib for patients with ALK-positive NSCLC following treatment
with crizotinib. The addition of this new ALK-targeted TKI into
the ALK mutation-positive treatment paradigm pushes the use of
a platinum doublet or single agent into the third line. As the treat-
ment of ALK-positive patients evolves, we can expect treatment
paradigms to continue to shift.
GROUP C: MUTATION STATUS NEGATIVE OR UNKNOWN
FIRST LINE
Patients with advanced NSCLC who have no known muta-
tions in the EGFR or ALK genes or whose mutation status is
unknown, receive the standard of care: a platinum doublet fea-
turing pemetrexed or gemcitabine for four to six cycles. While
there are many doublets to choose from in the first line includ-
ing cisplatin/paclitaxel, cisplatin/gemcitabine, cisplatin/docetaxel,
carboplatin/paclitaxel (1), the pivotal Scagliotti trial (17) demon-
strated that patients with adenocarcinoma fare better with cis-
platin/pemetrexed than cisplatin/gemcitabine in the first line (OS
12.6 versus 10.9 months; HR, 0.84; 95% CI, 0.71–0.99; superiority
P= 0.033).
ANOTHER DECISION POINT: MAINTENANCE AFTER FIRST LINE
Maintenance therapy is the focus of another article in this journal
(18). This therapeutic approach is important enough that it will
be addressed in this article as well, albeit briefly.
Maintenance therapy in NSCLC is defined as a therapeu-
tic agent that is administered after completion of the first line,
but before the disease progresses. Results suggest that NSCLC
patients may be more likely to receive additional therapy if main-
tenance is offered immediately after front-line therapy, before
progression occurs (19–21). A recent meta-analysis of 13 main-
tenance chemotherapy trials demonstrated an improvement in
PFS and in OS in patients who had experienced maintenance
therapy (22). The most promising strategies involved administer-
ing an approved second-line NSCLC therapeutic for maintenance
therapy (23, 24).
There are two types of maintenance therapy to consider, con-
tinuous and switch maintenance. Continuous maintenance is
when patients are offered one of the agents in the induction
doublet to be continued after first-line therapy until progres-
sion. This is an option for patients who have not progressed
on first line. The PARAMOUNT trial demonstrated that peme-
trexed maintenance given to NSCLC patients with tumors having
non-squamous histology after first-line platinum/pemetrexed had
a significantly reduced risk of disease progression over placebo
(20). Switch maintenance, also referred to as “early second line,”
is when a new agent is given after the completion of four cycles
of first-line-doublet. Studies have shown that both pemetrexed
(19) and erlotinib (21) improve both PFS and OS when admin-
istered as maintenance therapy after first-line chemotherapy is
completed.
To ask our patients to take maintenance therapy requires care-
ful discussion and consideration. Residual nausea, fatigue, and
alopecia from chemotherapy can take time to resolve, and many
patients may choose to have drug holiday after 3–4 months of
a platinum regimen. Many may refuse maintenance therapy as
it requires monitoring visits in addition to treatment. Patients
who decline maintenance therapy should be observed closely until
progression so that they may receive another line of therapy.

























































Melosky Treatment algorithms for NSCLC
FIGURE 2 | Oncogenic drivers in lung adenocarcinoma (27–29).
SECOND LINE
Proven second-line options for patients whose tumors are muta-
tion negative or mutation unknown, include docetaxel (23),
erlotinib (25), and pemetrexed (26). Pemetrexed can only be
offered if it was not used in first-line or maintenance therapy. If a
pemetrexed platinum doublet was selected in the first line or for
maintenance, docetaxel or erlotinib is selected for the second line.
The BR-21 trial demonstrated that erlotinib prolongs sur-
vival in patients with NCSLC following the failure of first-line
or second-line chemotherapy (25). This multicenter, random-
ized, controlled, Phase III study randomized patients who had
failed first- or second-line chemotherapy to either erlotinib or to
placebo. Patient selection was not based on EGFR status, gender,
smoking history, or type of NSCLC. The study met its primary
endpoint of improving OS (median OS of 6.7 versus 4.7 months
(HR, 0.70; 95 CI, 0.58–0.85; P < 0.001), and demonstrated sta-
tistically significant effects in secondary endpoints including PFS,
time to symptom deterioration, and response rate. Overall, 8.9%
of patients achieved an objective response to erlotinib (P < 0.001);
the median duration of response was 34.2 weeks. This trial demon-
strated a survival benefit in all patients regardless of EGFR muta-
tion status or histology (25). Although still controversial, BR-21
led to an EGFR TKI to become standard of care in second and
third line in unselected patients with NSCLC.
THIRD LINE
Third line therapies for mutation negative or mutation unknown
patients may include whatever agents were not given in previ-
ous lines. This may include docetaxel (23), erlotinib (25), and
pemetrexed (26). A significant limitation of therapy selection is
that few trials have tested these different agents in later therapy,
and sequences and combinations of these therapies have not been
tested. Third line therapy is continued until disease progression or
undue toxicity. After disease progression patients with adequate
performance status may be considered for clinical trials.
CONCLUSION
Although we test for EGFR and ALK mutations and have treat-
ments for those patients, therapy is still palliative in nature.
Chemotherapy still remains our therapeutic backbone. However,
the treatment algorithm will always be changing. As we continue to
define the drivers of thoracic malignancy (Figure 2), our discov-
ery and understanding of mutations in non-squamous, NSCLC
will evolve. We will combine different targeted agents to overcome
the development of resistance and will learn about the best ways
to sequence these agents. Physicians should aim to provide three
lines of therapy to patients. The discovery of new molecular tar-
gets and the development of targeted therapy ultimately benefit
the patients with NSCLC.
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